Completed NA INTERVENTIONAL 1-arm NCT06030089

Plasma Dosage of Venetoclax in the Fup of AML Patients Treated With Aza + Ven (VENETACIBLE)

Plasma Dosage of Venetoclax in the Follow-up of Acute Myeloid Leukemias Ineligible for Intensive Chemotherapy in the First Line of Treatment and Treated With Azacitidine + Venetoclax. Pilot Study VENETACIBLE

Sponsor: Centre Hospitalier Universitaire de Nice

Conditions Acute Myeloid Leukemia

Interventions Pharmacokinetic sampling Toxicity assessments Venetoclax and azacitidine combination Vital status determination

Updated 6 times since 2023 Last updated: Dec 8, 2025 Started: Feb 26, 2024 Primary completion: Sep 30, 2024 Completion: Mar 3, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06030089, this NA trial focuses on Acute Myeloid Leukemia and remains completed. Sponsored by Centre Hospitalier Universitaire de Nice, it has been updated 6 times since 2024, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Jan 2026 — Present [monthly]

Completed NA

Status: Active Not Recruiting → Completed
Dec 2024 — Jan 2026 [monthly]

Active Not Recruiting NA

Status: Recruiting → Active Not Recruiting
Sep 2024 — Dec 2024 [monthly]

Recruiting NA
Jul 2024 — Sep 2024 [monthly]

Recruiting NA
Apr 2024 — Jul 2024 [monthly]

Recruiting NA

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Oct 2023 — Apr 2024 [monthly]

Not Yet Recruiting NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Centre Hospitalier Universitaire de Nice

Data source: Centre Hospitalier Universitaire de Nice

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Marseille, France
• Nice, France